Show simple item record

dc.contributor.authorGiovannoni, Gen_US
dc.contributor.authorMarta, Men_US
dc.contributor.authorDavis, Aen_US
dc.contributor.authorTurner, Ben_US
dc.contributor.authorGnanapavan, Sen_US
dc.contributor.authorSchmierer, Ken_US
dc.date.accessioned2016-09-05T11:15:12Z
dc.date.available2016-03-28en_US
dc.date.issued2016-10en_US
dc.date.submitted2016-05-10T19:15:01.314Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/14950
dc.description.abstractThere are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have risks that need to be managed, for example, the risks of carrying over asymptomatic PML from natalizumab on to the new therapy, and the risk of rebound disease activity associated with a prolonged washout after starting natalizumab. We propose a pragmatic bridging strategy, using another disease-modifying therapy (DMT), to reduce the risk of switching from natalizumab to alemtuzumab. We also discuss the caveats and subtleties associated with sequencing DMTs in MS and the complex decision making involved.en_US
dc.format.extent389 - 393en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofPract Neurolen_US
dc.subjectAlemtuzumaben_US
dc.subjectMULTIPLE SCLEROSISen_US
dc.subjectNatalizumaben_US
dc.subjectPMLen_US
dc.subjectprogressive multifocal leukoencephalopathyen_US
dc.subjectAlemtuzumaben_US
dc.subjectHumansen_US
dc.subjectImmunologic Factorsen_US
dc.subjectLeukoencephalopathy, Progressive Multifocalen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectNatalizumaben_US
dc.titleSwitching patients at high risk of PML from natalizumab to another disease-modifying therapy.en_US
dc.typeArticle
dc.rights.holder© 2016, British Medical Journal Publishing Group
dc.identifier.doi10.1136/practneurol-2015-001355en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/27114560en_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute/Neuroscience and Trauma
pubs.organisational-group/Queen Mary University of London/REF
pubs.organisational-group/Queen Mary University of London/REF/REF - Blizard
pubs.publication-statusPublisheden_US
pubs.volume16en_US
dcterms.dateAccepted2016-03-28en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record